Cytodyn Inc (CYDY)

[Bill_ENG]

I was referring to the whole trial not the Critical. Since we were speaking to the Trial results as a failure.

The bigger advantage would be the younger in the severe as they have a stronger natural immune system than the older patients and that would be where the biggest change to the total trial results would be.

But lets talk about the Critical.

Critical was total of 62 Patients.

65 and less was total of 44.
29 in LL + SOC resulting in 3 deaths for 10%
15 in Placebo + SOC resulting in 4 deaths for 27%

We know that CDC says 8 of 10 deaths due to Covid19 are 65 and over. That would suggest that 2 of 10 are under 65 for 20%.

You could suggest that LL fared better due to more 65 and under but they still performed twice as well as the average touted by the CDC.

Over 65 LL still performed better.

65% for LL vs 75% placebo and like I said, that is with 1/2 treatment.

CDC touts over 65 as 80% of deaths. LL was at 65% at 2 weeks of treatment in a 4 week trial. At 14 days while Leronlimab still circulating in the body was at 18% mortality.

80% Mortality or 18% mortality ?

JMO